Manuscripts
Showing 1552 manuscripts.
Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration
Citation
Edward R. Cachay, Niousha Moini, Sergei L. Kosakovsky Pond, Rick L. Pesano, Yolanda Lie, Heidi Aiem, David M. Butler, Scott L. Letendre, W. Christopher Mathews, Davey M. Smith. Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration. The Open AIDS Journal. 2007. 1: 5-10.Year
2007
Journal
The Open AIDS Journal
Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis
Citation
Susan L Rosenkranz, Kevin E. Yarasheski, Michael F. Para, Richard C. Reichman, Gene D. Morse. Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis. Metabolic Syndrome and Related Disorders. 2007. 5: 163-73.Year
2007
Journal
Metabolic Syndrome and Related Disorders
Reproductive health of adolescent girls perinatally infected with HIV.
Citation
Susan Brogly, Heather D. Watts, Nathalie Ylitalo, E. L. Franco, George Seage, James M. Oleske, Michelle L. Eagle, Russell B. Van Dyke. Reproductive health of adolescent girls perinatally infected with HIV.. American Journal of Public Health. 2007. 97: 1047-1052. PMID: 17463385Year
2007
Journal
American Journal of Public Health
Participation of HIV-infected pregnant women in research in the United States
Citation
David Shapiro, Alice M Stek, Ruth Tuomala, Susan Brogly, Jennifer S Read. Participation of HIV-infected pregnant women in research in the United States. AIDS Research and Human Retroviruses. 2007. 23: 51 - 53. PMID: 17263632Year
2007
Journal
AIDS Research and Human Retroviruses
Study
P1025
Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.
Citation
Akihiko Saitoh, Courtney V. Fletcher, Richard Brundage, Carmelita Alvero, Terence Fenton, Karen Hsia, Stephen A. Spector. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.. Journal of Acquired Immune Deficiency Syndromes. 2007. 45: 280 - 285. PMID: 17356468Year
2007
Journal
Journal of Acquired Immune Deficiency Syndromes
Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.
Citation
Carmen D. Zorrilla, Russell B. Van Dyke, Arlene D. Bardeguez, Edward P. Acosta, Elizabeth (Betsy) Smith, Michael Hughes, Sharon Huang, Heather D. Watts, Barbara E. Heckman, Barbara E. Heckman, Eleanor Jimenez, George D. McSherry, Lynne M. Mofenson. Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.. Antimicrobial Agents and Chemotherapy. 2007. 51: 2208 - 2210. PMID: 17420209Year
2007
Journal
Antimicrobial Agents and Chemotherapy
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels. Results of a prospective randomized trial (AIDS clinical trial group 5125s)
Citation
Pablo Tebas, Jiameng Zhang, Kevin E. Yarasheski, Scott Evans, Margaret A. Fischl, Abby Helen Shevitz, Judith Feinberg, Ann C. Collier, Cecilia M. Shikuma, Barbara Brizz, Fred Richard Sattler. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels. Results of a prospective randomized trial (AIDS clinical trial group 5125s). Journal of Acquired Immune Deficiency Syndromes. 2007. 45: 193-200.Year
2007
Journal
Journal of Acquired Immune Deficiency Syndromes
Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis
Citation
Nancy Radcliffe Reynolds, Junfeng Sun, Haikady N. Nagaraja, Allen L. Gifford, Albert W. Wu, Margaret A. Chesney. Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis. Journal of Acquired Immune Deficiency Syndromes. 2007. 46: 402-9.Year
2007
Journal
Journal of Acquired Immune Deficiency Syndromes
Phase 2 study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211
Citation
Daniel R. Kuritzkes, Roy (Trip) Gulick, Zhaohui Su, Charles Flexner, Michael Hughes, Paul Skolnik, Timothy J. Wilkin, Robert Gross, Amy Krambrink, Eoin Coakley, Wayne Greaves, Andrew R. Zolopa, Richard C. Reichman, Catherine Godfrey, Martin S. Hirsch. Phase 2 study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. Journal of Infectious Diseases. 2007. 196: 304-12.Year
2007
Journal
Journal of Infectious Diseases
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial
Citation
Bruce R. Schackman, Callie A. Scott, Paul Edward Sax, Elena Losina, Timothy J. Wilkin, John Ernest McKinnon, Susan Swindells, Milton C. Weinstein, Kenneth A. Freedberg. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clinical Infectious Diseases. 2007. 45: 1062-70.Year
2007
Journal
Clinical Infectious Diseases